Highlights
- India's investment banking industry generated an estimated $614.1 million in fees during H1 2026, down 20% year-on-year.
- M&A advisory fees bucked the broader trend, rising 24% to $265 million during the same period.
- Total India M&A deal value reached $86.9 billion in H1 2026, up 31% year-on-year, despite an 8% decline in deal volumes.
- Q2 2026 alone recorded $66.9 billion in deal value, more than three times the level seen in Q1 2026.
India's corporate finance landscape presented a study in contrasts during the first half of 2026, as the overall investment banking fee pool contracted even as fees tied specifically to mergers and acquisitions advisory work climbed sharply. The divergence reflects a market increasingly defined by a smaller number of very large transactions rather than a broad spread of mid-sized deals.
According to data compiled by LSEG and cited in industry reports, India's investment banking industry generated an estimated $614.1 million in fees during H1 2026, a 20% decline compared with the same period last year, even as M&A advisory fees rose 24% to $265 million.
Why Investors Are Watching
The bifurcated fee trend matters to market participants because it signals where corporate activity and capital deployment are concentrated. Rising M&A advisory income alongside falling overall fees suggests that large strategic transactions, rather than routine equity or debt issuance work, are driving corporate finance activity in India this year.
This has implications for how banks, advisory firms, and corporates approach deal-making in the second half of 2026, particularly as outbound acquisitions by Indian companies have become an increasingly important share of total deal value.
Market Context
India's M&A deal value reached $86.9 billion in H1 2026, marking a 31% year-on-year increase even though the number of transactions fell by 8%. The trend intensified through the year, with Q2 2026 deal value of $66.9 billion coming in at more than three times the level recorded in Q1, marking the highest quarterly M&A value since Q2 2022.
Outbound acquisitions by Indian companies accounted for 84% of total M&A value in Q2 2026, with combined outbound deal value rising more than sixfold from $3.87 billion in Q1 to $23.44 billion in Q2. Large transactions such as Sun Pharmaceutical Industries' acquisition of Organon & Co. and Bharti Airtel's transaction involving its African subsidiary contributed significantly to this outbound surge.
What Market Participants Will Monitor
Analysts will watch whether the concentration of deal value in a handful of very large transactions continues into the second half of 2026, or whether mid-market deal volumes recover to broaden the base of corporate finance activity. The mix between domestic consolidation and outbound acquisitions will also be closely tracked, given the outsized contribution of overseas deals to total value this year.
Sector-wise performance will also be monitored, with healthcare, industrials, and financial services having recorded robust deal activity in H1 2026, while the technology sector saw active deal counts but declining overall transaction value compared to other industries.
Industry or Peer Perspective
Global and domestic investment banks operating in India, along with corporate advisory and legal firms, are directly affected by this shift toward large, complex, cross-border transactions, which typically carry different fee structures and staffing requirements compared to routine domestic mandates.
Companies actively engaged in outbound consolidation, such as Sun Pharmaceutical Industries (NSE:SUNPHARMA) and Bharti Airtel (NSE:BHARTIARTL), serve as reference points for how large Indian corporates are using M&A to expand their global footprint even as overall deal volumes in the domestic market moderate.
Conclusion
The divergence between falling overall investment banking fees and rising M&A advisory income in H1 2026 underscores a corporate finance environment shaped by a small number of transformative transactions rather than broad-based deal activity. With outbound M&A driving an outsized share of total value, the second half of 2026 will show whether this concentration persists or gives way to a more diversified deal landscape.
FAQs
Q: Why is the company in focus today?
A: This report focuses on India's broader investment banking and M&A advisory fee trends in H1 2026, rather than a single company, highlighting a divergence between falling overall fees and rising M&A advisory income.
Q: What factors are investors monitoring?
A: Market participants are monitoring the concentration of deal value in large transactions, the share of outbound versus domestic M&A, and whether mid-market deal volumes recover in the second half of 2026.
Q: Which peer companies are relevant?
A: Sun Pharmaceutical Industries (NSE:SUNPHARMA) and Bharti Airtel (NSE:BHARTIARTL) are relevant given their large outbound transactions that contributed significantly to H1 2026 M&A deal value.
Q: Is this article investment advice?
A: No. This article is intended solely for informational purposes and should not be considered investment, financial or trading advice.